e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Defi Technologies, Inc. - Common Stock
Thunder Bridge Capital Partners IV, Inc. - Unit
Edit Watchlist
Indicators
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by PolarityBio
Dr. Robert Langer, Co-Founder of Moderna, Joins PolarityBio’s Board of Directors
November 16, 2026
From
PolarityBio
Via
GlobeNewswire
PolarityBio Highlights Highest Scoring Abstract Award and Presentation of Phase 3 COVER DFUS II Trial Results at SAWC Fall 2026
October 20, 2026
From
PolarityBio
Via
GlobeNewswire
PolarityBio’s Phase 3 COVER DFUS II Trial Selected for First-to-Podium Presentation at SAWC Fall 2026
September 29, 2026
From
PolarityBio
Via
GlobeNewswire
PolarityBio Announces FDA Acceptance for Filing of SkinTE® BLA with Priority Review in Diabetic Foot Ulcers
September 15, 2026
From
PolarityBio
Via
GlobeNewswire
PolarityBio Announces Submission of its Biologics License Application for SkinTE® for the Treatment of Wagner Grade 1 Diabetic Foot Ulcers
July 01, 2026
From
PolarityBio
Via
GlobeNewswire
PolarityBio Announces AMA Publication of New Category III CPT Codes for SkinTE® Procedures
January 05, 2026
From
PolarityBio
Via
GlobeNewswire
PolarityBio Completes Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers
December 02, 2025
From
PolarityBio
Via
GlobeNewswire
PolarityBio Announces Acceptance of Category III CPT® Code Application for Autologous Heterogeneous Skin Construct Graft by AMA CPT® Editorial Panel
October 29, 2025
From
PolarityBio
Via
GlobeNewswire
PolarityBio Announces Launch of Expanded Access Treatment Protocol to Provide Continued Access to SkinTE® for Patients with Wagner 1 Diabetic Foot Ulcers
September 02, 2025
From
PolarityBio
Via
GlobeNewswire
PolarityBio to Share Regenerative Wound Healing Expertise at SAWC Fall 2025
August 28, 2025
From
PolarityBio
Via
GlobeNewswire
PolarityBio Completes Enrollment in the Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers
August 26, 2025
From
PolarityBio
Via
GlobeNewswire
PolarityBio Receives U.S. FDA Breakthrough Therapy Designation for Treatment of Wagner Grade I Diabetic Foot Ulcers (DFU)
February 20, 2025
From
PolarityBio
Via
GlobeNewswire
PolarityBio Announces Interim Enrollment Achieved in SkinTE’s Phase III Pivotal Study
December 03, 2024
From
PolarityBio
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.